Respiratory Diagnostics Market: Growth, Size, Share, and Trends

Report Code MD 4740
Published in Feb, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

Respiratory Diagnostics Market by Product & Services (Instrument & Devices), Test type (Mechanical, OSA, Imaging, Molecular Test), Disease (Tuberculosis, COPD, Lung Cancer ) and Diagnosis Type (Syndromic, Aetiological, Prognosis) - Global Forecast to 2030

Overview

The global respiratory diagnostics market, valued at US$5.85 billion in 2023, is forecasted to grow at a robust CAGR of 6.5%, reaching US$6.17 billion in 2024 and an impressive US$9.02 billion by 2030. Respiratory diagnostic devices help detect respiratory disorders. These constitute various instruments, devices, assays, and reagents. Diagnostic tests for respiratory evaluation include mechanical evaluation, such as spirometry, pulse oximetry, and bronchoscopy; imaging studies; and in vitro studies. The market comprises analyzers, sequencers, amplifiers, and electrophoresis systems; assays & reagents; services & software for diagnosing diseases such as tuberculosis, asthma, lung cancer, and chronic obstructive pulmonary disease (COPD).

The major factors driving the growth of this market include the rising incidence of respiratory disorders, the expanding geriatric population and the rise in sedentary lifestyles, growing awareness about respiratory health, and advancements in diagnostic technologies. The high growth potential of emerging economies, the increasing demand for POC testing, and the growing awareness about obstructive sleep apnea (OSA) are factors expected to create growth opportunities for market players during the forecast period.

Respiratory Diagnostics Market – Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the Respiratory Diagnostics Market

Asia Pacific

Market growth in the Asia Pacific region can be attributed to the rising geriatric population, growing per capita income, and favorable investments for improvements in healthcare infrastructure. The rising incidence of infectious diseases is also expected to fuel the uptake of advanced respiratory diagnostics during the forecast period.

The rising prevalence of respiratory disorders and the increasing incidence of respiratory infections owing to the high level of air pollutants is expected to drive market growth during the forecast period.

The growing demand for POC diagnostics and the high growth potential of emerging economies is expected to provide lucrative growth opportunities for market players.

The Asia Pacific respiratory diagnostics market is expected to be worth USD 2.1 billion by 2030, growing at the highest CAGR of 7.3% during the forecast period.

The high cost of diagnostic tests and limited reimbursements are expected to restrain the market growth to a certain extent.

Global Respiratory Diagnostics Market Dynamics

DRIVER: Increasing incidence of respiratory disorders

Respiratory ailments like chronic obstructive pulmonary disease (COPD), asthma, lung cancer, and respiratory infections have increasingly become more prevalent through urbanization, pollution, smoking, and the expansive geriatric population worldwide. This prevalence is expected to lead to the demand for advanced diagnostic tools such as spirometry, molecular diagnostics, imaging technologies, and blood gas analyzers for the diagnosis & treatment of respiratory conditions. According to Springer Nature and NCBI, COPD as an illness is the third-leading cause of death in 2023, with 12% of the overall population being recorded to be afflicted with the condition, with 3 million deaths reported in a year. Projections show that 5.4 million deaths will be attributed to COPD by 2060. According to the EU, there is a cost implication of USD 40.14 billion in terms of economic burden subtended by the disease annually. In 2023, in the US, about 4.3% of people have been diagnosed with COPD, emphysema, or chronic bronchitis. Therefore, the rising incidence of such diseases and the growing need for preventive care are key factors contributing to market growth during the forecast period.

RESTRAINT: High cost of diagnostic tests

Serious discrepancies in the costs of respiratory diagnostic tests, especially in low- and middle-income countries, are expected to limit test uptake during the forecast period. The high cost of diagnostic technologies such as molecular assay tests for conditions such as multidrug-resistant tuberculosis (MDR-TB) further makes patients spend 'mostly out-of-pocket' because of poor insurance or limited public health help. Delayed diagnosis owing to high costs increases the burden of diseases and drives the demand on healthcare facilities for diagnostic services. Therefore, the nonavailability of cost-effective solutions is expected to impact the market's growth significantly during the forecast period.

 

OPPORTUNITY: Growing awareness of untreated sleep apnea

The increasing understanding of the consequences of untreated sleep apnea offers immense potential for respiratory diagnostics. According to ResMed, in the US, the cost of untreated OSA ranges from USD 43 billion to USD 46 billion, whereas undiagnosed cases generate an additional USD 3.4 billion in medical expenses. Similarly, OSA increases the risk for several health outcomes—140% increased risk for heart failure, 60% increased risk for stroke, and 30% increased risk for coronary heart disease. It is also linked to type 2 diabetes, cognitive deficits, and other health problems. Such considerations have triggered healthcare stakeholders, including government institutions, physicians, and primary stakeholders in the market, to implement programs designed to create awareness concerning the early diagnosis & management of sleep apnea. The trend thus fuels the demand for diagnostic solutions to counter the effects of undiagnosed OSA.

CHALLENGES: Complexities associated with diagnosis of respiratory infectious diseases

Overlapping clinical symptoms with bacterial infection and other conditions like asthma or COPD complicate the diagnosis of viral respiratory infections since these viruses are continuously changing, with most current viral examples being variants of influenza, RSV, and SARS-CoV-2 that could evade existing diagnostic tools. According to the CDC report on RSV in 2022, RSV alone causes 58,000-80,000 hospitalizations annually in the US for children under five; most children, 60-70%, have had an RSV infection by age one. Antigen detector assays, serological tests, and nucleic acid amplification tests (NAATs) are diagnostic technologies developed in recent years. However, each has limitations: rapid immunoassays are limited to specific viruses; serological tests are of little clinical use; and the cost of NAATs is high, coupled with the complexity of PCR, where it may not be feasible in resource-poor settings. Although NAATs, particularly PCR tests, are regarded as the "gold standard" for precision and reliability, the high costs and complexities may restrict widespread implementation, especially in resource-limited settings. This convoluted scenario mandates the rising need for adaptable & low-cost solutions to address the effective prevention of diverse and evolving respiratory pathogens.

Global Respiratory Diagnostics Market Ecosystem Analysis

Leading players in this market include well-established and financially stable service providers of respiratory diagnostics. These companies have been operating in the market for several years and possess a diversified product portfolio, advanced technologies, and a strong global presence.

Respiratory Diagnostics Market Ecosystem
 

By product & service, the assays & reagents segment is expected to grow at the highest CAGR during the forecast period.

By product & service, the market is segmented into instruments & devices, assays & reagents, and services & software. The assays & reagents segment is expected to grow at the highest CAGR during the forecast period. This high growth rate of this segment is attributed to the increasing demand for advanced & highly effective assay reagents; improvements in manufacturing capabilities for consumables; and the growing volume of diagnostic samples. Assays & reagents are single-use consumables with a relatively shorter shelf life; hence, steady replenishments contribute to further growth of this segment.

By test type, the mechanical tests segment accounted for the largest market share in 2023.

The mechanical tests segment accounted for the largest share of the market as there has been an increase in respiratory health awareness along with advancements in various diagnostic methods. The mechanical test segments are further bifurcated into pulmonary function tests, obstructive sleep apnea diagnostics tests, and other mechanical tests. The pulmonary function tests segment is sub-segmented into three categories: spirometry, peak flow tests, and other pulmonary function tests. Respiratory conditions are being addressed widely, and there is an increasing demand for accurate and reliable diagnostic tests. Increased awareness about health and technological improvement is favoring the market growth for the mechanical test segment in 2023.

By disease type, the COPD segment is estimated to grow at the highest CAGR during the forecast period.

By disease type, the respiratory diagnostics market includes COPD, asthma, tuberculosis, lung cancer, and other diseases. The COPD segment is estimated to grow at the highest CAGR, owing to the increasing prevalence of COPD in young adults & elders, the rising consumption of tobacco products, and the increasing frequency of being exposed to environmental pollutants. Moreover, worsening air quality in emerging markets is expected to further propel the demand for respiratory diagnostics for COPD patients during the forecast period.

By diagnosis type, the syndromic segment accounted for the largest market share in 2023

The syndromic segment accounted for the largest market share in 2023. This methodology detects complex genetic disorders that overlap in phenotypical appearances. Some factors associated with the growth trend include the growing need for early and accurate diagnosis, advancements in diagnostic technologies, and increasing healthcare investments.

By end user, the hospitals & clinics segment is expected to grow at the highest CAGR during forecast period.

By end user, the hospitals segment dominated the respiratory diagnostics market. The key factors contributing to the market growth of this segment can be attributed to factors such as the high purchasing rate of hospitals to buy large ticketing equipment for respiratory diagnostics and the increasing footfall of patients in this end-user segment. The high healthcare expenditure of hospitals; rising technological advancements in diagnostics technologies; and the uptake of technologically advanced solutions across hospitals are also expected to fuel market growth of this segment.

The Asia Pacific region is estimated to grow at the highest CAGR during the forecast period.

By region, the Asia Pacific market is expected to dominate the respiratory diagnostics market during the forecast period. The gradual increase in healthcare spending across emerging economies is expected to drive enhanced healthcare outcomes and the uptake of technologically advanced diagnostics. The rising establishment of several diagnostic laboratories in the region is expected to lower the cost of respiratory diagnostics. The increasing number of medical device manufacturers in the region is also expected to contribute to market growth.

Respiratory Diagnostics Market Region

Recent Developments of Respiratory Diagnostics Market

  • In September 2024, Becton, Dickinson and Company (US) acquired Edwards Lifesciences Corporation’s Critical Care product group. The product group is now renamed BD Advanced Patient Monitoring, unlocking new value opportunities and enhancing BD's innovative connected care solutions portfolio.
  • In June 2024, bioMérieux (France) declared that the BIOFIRE SPOTFIRE Respiratory/Sore Throat (R/ST) Panel Mini has received the US FDA Special 510(k) approval and CLIA-waiver (Clinical Laboratory Improvement Amendments). This unique multiplex PCR test detects five of the most common viral & bacterial causes of respiratory or sore throat infections in about 15 minutes.
  • In January 2024, Wipro GE Healthcare, a Joint Venture (JV) between GE Precision Healthcare LLC (US) and Wipro Enterprises Limited (India), signed a MoU with the Indian Institute of Science (IISc) (India) to advance healthcare innovation, research, and technology development in India.
  • In August 2023, Bio-Rad Laboratories, Inc. (US) launched two products, PTC Tempo 48/48 and PTC Tempo 384, designed to support PCR applications in basic and translational research, process development, and quality control.

Key Market Players

KEY PLAYERS IN THE RESPIRATORY DIAGNOSTICS MARKET INCLUDE

Want to explore hidden markets that can drive new revenue in Respiratory Diagnostics Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2030
Base Year Considered 2023
Forecast period 2024-2030
Forecast units Value (USD million/billion)
Segments covered Product and Servic, Test Type, Disease Indication, Type of Diagnosis, End user and Region
Geographies covered North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa

 

Key Questions Addressed by the Report

What are the emerging trends in the respiratory diagnostics market?
The growing demand for enhanced POC devices, the importance of digitized devices, and reagent rentals are expected to be the key market trends in the respiratory diagnostics market.
Which segments have been included in this report?
This report has the following segments:
  • By Product & Service
  • By Test Type
  • By Disease Type
  • By Diagnosis Type
  • By End User
  • By Region
Which are the top industry players in the respiratory diagnostics market?
The top market players in the global respiratory diagnostics market are Koninklijke Philips N.V. (Netherlands), Becton, Dickinson and Company (US), Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), GE HealthCare Technologies Inc. (US), and Bio-Rad Laboratories, Inc. (US), among others.
What are the factors expected to pose a challenge to the growth of the respiratory diagnostics market?
Complexities associated with the diagnosis of viral respiratory infections and the limited access to peripheral lung lesions in bronchoscopy are factors expected to challenge this market's growth during the forecast period.
By product & service, which segment accounted for the largest share of the respiratory diagnostics market in 2023?
The instruments & services segment accounted for the largest market share in 2023. The large share of this segment can be attributed to the expansion of diagnostic labs in emerging markets; the increasing number of buyers for diagnostics tests; rising technological advancements in instruments; and the trend of reagents on a rental basis.

 

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Respiratory Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table Of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
33
RESEARCH METHODOLOGY
38
EXECUTIVE SUMMARY
52
PREMIUM INSIGHTS
56
MARKET OVERVIEW
59
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing incidence of respiratory disorders
    - Expanding geriatric population and rise in sedentary lifestyles
    - Growing awareness about respiratory health
    - Advancements in diagnostic technologies
    RESTRAINTS
    - High cost of diagnostic tests
    - Limited reimbursements
    - Shortage of skilled professionals
    OPPORTUNITIES
    - High growth potential of emerging economies
    - Increasing demand for POC testing
    - Growing awareness about untreated OSA
    CHALLENGES
    - Complexities associated with diagnosis of viral respiratory infections
    - Limited access to peripheral lung lesions in bronchoscopy
  • 5.3 INDUSTRY TRENDS
    POINT-OF-CARE TESTING
    PERSONALIZED MEDICINE
  • 5.4 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Home-based & personal DHTs
    - PFT tools and molecular & imaging diagnostics
    COMPLEMENTARY TECHNOLOGIES
    - AI-enhanced imaging
    - Serological & telehealth platforms
    ADJACENT TECHNOLOGIES
    - Rapid respiratory diagnostic tests
  • 5.5 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.6 REGULATORY ANALYSIS
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    REGULATORY LANDSCAPE
    - North America
    - Europe
    - Asia Pacific
    - Latin America
    - Middle East & Africa
  • 5.7 PATENT ANALYSIS
    KEY PATENTS GRANTED
  • 5.8 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 901819
    EXPORT DATA FOR HS CODE 901819
  • 5.9 PRICING ANALYSIS
    AVERAGE SELLING PRICE OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY KEY PLAYER (2024)
    AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY REGION, 2021–2023
  • 5.10 VALUE CHAIN ANALYSIS
  • 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.12 KEY CONFERENCES & EVENTS, 2024–2025
  • 5.13 UNMET NEEDS/END-USER EXPECTATIONS
  • 5.14 ADJACENT MARKET ANALYSIS
  • 5.15 ECOSYSTEM ANALYSIS
  • 5.16 CASE STUDY ANALYSIS
  • 5.17 SUPPLY CHAIN ANALYSIS
  • 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.19 INVESTMENT & FUNDING SCENARIO
  • 5.20 REIMBURSEMENT SCENARIO
  • 5.21 IMPACT OF AI/GENERATIVE AI ON RESPIRATORY DIAGNOSTICS MARKET
RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
100
  • 6.1 INTRODUCTION
  • 6.2 INSTRUMENTS & DEVICES
    INTRODUCTION OF AUTOMATED & HIGH-THROUGHPUT INSTRUMENTS TO DRIVE MARKET
  • 6.3 ASSAYS & REAGENTS
    INCREASING DEMAND FOR RESPIRATORY DIAGNOSTIC TEST KITS TO PROPEL MARKET
  • 6.4 SERVICES & SOFTWARE
    INCREASING DEMAND FOR CONSISTENT UPGRADES AND SUPPORT SERVICES TO FUEL MARKET
RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE
106
  • 7.1 INTRODUCTION
  • 7.2 MECHANICAL TESTS
    PULMONARY FUNCTION TESTS
    - Spirometry
    - Peak flow tests
    - Other pulmonary function tests
    OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS
    - Large presence of untreated population to drive market
    OTHER MECHANICAL TESTS
  • 7.3 IMAGING TESTS
    X-RAY
    - Integration of AI into X-ray devices for enhanced imaging capabilities to drive market
    COMPUTED TOMOGRAPHY
    - Rising focus on obtaining high-resolution CT images to boost demand
    MAGNETIC RESONANCE IMAGING (MRI)
    - Ability to provide detailed lung images without radiation exposure to drive market
    POSITRON EMISSION TOMOGRAPHY (PET)
    - Growing focus on detection & monitoring of treatment response to lung cancer to drive market
    OTHER IMAGING TESTS
  • 7.4 TRADITIONAL DIAGNOSTIC TESTS
    IMMUNODIAGNOSTICS
    - Rising demand for rapid disease diagnosis to fuel uptake
    BIOCHEMICAL TESTS
    - Ability to accurately measure biomarkers in pneumonia and bronchitis infections to boost demand
    MICROSCOPY
    - Inadequate sensitivity towards emerging viruses to restrain market
  • 7.5 MOLECULAR DIAGNOSTIC TESTS
    POLYMERASE CHAIN REACTION (PCR)
    - Development of portable and real-time PCR machines to drive market
    NUCLEIC ACID AMPLIFICATION TEST (NAAT)
    - Rapid identification of viral, bacterial, and fungal infections to fuel demand
    IN SITU HYBRIDIZATION (ISH)
    - Utilization of probes for pathogen detection to support market growth
    DNA SEQUENCING & NEXT-GENERATION SEQUENCING (NGS)
    - High-throughput capabilities for rapid analysis of genetic data to propel market
    MICROARRAYS
    - Detection of hepatitis C and respiratory viruses to support market growth
    OTHER MOLECULAR DIAGNOSTIC TESTS
RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE
141
  • 8.1 INTRODUCTION
  • 8.2 TUBERCULOSIS
    FAVORABLE FUNDING INITIATIVES FOR TB TREATMENT TO DRIVE MARKET
  • 8.3 ASTHMA
    INCREASING AIR POLLUTION AND GROWING USE OF TOBACCO-BASED PRODUCTS TO DRIVE MARKET
  • 8.4 LUNG CANCER
    NON-SMALL-CELL LUNG CANCER (NSCLC)
    - Rising investments in advanced radiographic technologies to fuel market
    SMALL-CELL LUNG CANCER (SCLC)
    - Growing emphasis on precision testing to drive market
    OTHER LUNG CANCERS
  • 8.5 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
    ADVANCEMENTS IN SPIROMETRY AND PLETHYSMOGRAPHY FOR COPD DIAGNOSIS TO FUEL MARKET
  • 8.6 PNEUMONIA
    RISING INCIDENCE OF RESPIRATORY INFECTIONS TO BOOST DEMAND
  • 8.7 OTHER DISEASES
RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE
154
  • 9.1 INTRODUCTION
  • 9.2 SYNDROMIC DIAGNOSIS
    DETECTION OF MULTIPLE PANELS OF VIRAL PATHOGENS TO PROPEL MARKET
  • 9.3 ETIOLOGICAL DIAGNOSIS
    IDENTIFICATION OF SPECIFIC CAUSE OF RESPIRATORY ILLNESSES TO FUEL MARKET
  • 9.4 PROGNOSIS DIAGNOSIS
    ASSESSMENT OF BIOMARKERS FOR DISEASE PROGRESSION TO SUPPORT MARKET GROWTH
RESPIRATORY DIAGNOSTICS MARKET, BY END USER
160
  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS & CLINICS
    GROWING ACCESSIBILITY TO ADVANCED EQUIPMENT TO FUEL MARKET
  • 10.3 DIAGNOSTIC LABORATORIES
    ABILITY TO PROVIDE AFFORDABLE TESTING PROCESSES WITH TIMELY RESULTS TO BOOST DEMAND
  • 10.4 LONG-TERM CARE & SPECIALTY CENTERS
    PROVISION OF SPECIALIZED & ADVANCED SERVICES TO PROPEL MARKET
  • 10.5 ACADEMIC & RESEARCH INSTITUTES
    FAVORABLE FUNDING INITIATIVES TO SUPPORT MARKET GROWTH
RESPIRATORY DIAGNOSTICS MARKET, BY REGION
166
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    - Growing accessibility to technologically advanced products to boost demand
    CANADA
    - Rising incidence of COPD to drive market
  • 11.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    - Increasing public healthcare expenditure to foster market growth
    UK
    - Rising establishment of hospitals and increasing number of surgical procedures to fuel market
    FRANCE
    - High prevalence of smoking and increasing demand for respiratory devices to drive market
    ITALY
    - Unfavorable amendments to healthcare policies to restrain market
    SPAIN
    - Increasing demand for home healthcare services to support market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    JAPAN
    - Availability of universal healthcare reimbursement policy to drive market
    CHINA
    - High incidence of viral respiratory infections to propel market
    INDIA
    - Expansion of leading medical device manufacturers and large target patient population to drive market
    AUSTRALIA
    - High prevalence of chronic lung diseases to boost demand
    SOUTH KOREA
    - Expanding geriatric population and rising incidence of chronic respiratory conditions to fuel market
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    - Favorable government initiatives for healthcare sector improvement to drive market
    MEXICO
    - Rising prevalence of obesity & hypertension to fuel uptake
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
    GCC COUNTRIES
    - Kingdom of Saudi Arabia (KSA)
    - United Arab Emirates (UAE)
    - Other GCC Countries
    REST OF MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
290
  • 12.1 INTRODUCTION
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, JANUARY 2021–DECEMBER 2024
  • 12.3 REVENUE ANALYSIS, 2019–2023
  • 12.4 MARKET SHARE ANALYSIS, 2023
    RANKING OF KEY MARKET PLAYERS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Region footprint
    - Product & service footprint
    - Test type footprint
    - Disease type footprint
    - End-user footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 BRAND/PRODUCT COMPARISON
  • 12.8 R&D EXPENDITURE OF KEY PLAYERS
  • 12.9 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 12.10 COMPETITIVE SCENARIO
    PRODUCT & SERVICE LAUNCHES AND APPROVALS
    DEALS
    EXPANSIONS
    OTHER DEVELOPMENTS
COMPANY PROFILES
313
  • 13.1 KEY PLAYERS
    KONINKLIJKE PHILIPS N.V.
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    BECTON, DICKINSON AND COMPANY
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    ABBOTT LABORATORIES
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    GE HEALTHCARE TECHNOLOGIES, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    - MnM view
    BIO-RAD LABORATORIES, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products & services offered
    - Recent developments
    REVVITY, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    SEEGENE INC.
    - Business overview
    - Products & services offered
    - Recent developments
    NIHON KOHDEN CORPORATION
    - Business overview
    - Products & services offered
    VITALOGRAPH
    - Business overview
    - Products & services offered
    - Recent developments
    SDI DIAGNOSTICS
    - Business overview
    - Products & services offered
    RESMED INC.
    - Business overview
    - Products & services offered
    - Recent developments
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products & services offered
    - Recent developments
    COSMED SRL
    - Business overview
    - Products & services offered
    - Recent developments
    HOLOGIC, INC.
    - Business overview
    - Products & services offered
    - Recent developments
    QIAGEN N.V.
    - Business overview
    - Products & services offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    MGC DIAGNOSTICS CORPORATION
    VISBY MEDICAL, INC.
    BRIOTA TECHNOLOGIES PVT. LTD.
    BIRD HEALTHCARE
    LÖWENSTEIN MEDICAL SE & CO. KG
    PROAXSIS
    NDD MEDICAL TECHNOLOGIES
    COMPUMEDICS LIMITED
APPENDIX
391
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 RESPIRATORY DIAGNOSTICS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
  • TABLE 3 RESPIRATORY DIAGNOSTICS MARKET: STUDY ASSUMPTIONS
  • TABLE 4 RESPIRATORY DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 5 AWARENESS INITIATIVES ON EFFECTS OF UNTREATED SLEEP APNEA
  • TABLE 6 RESPIRATORY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 US: CLASSIFICATION OF MEDICAL EQUIPMENT
  • TABLE 13 US: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 14 CANADA: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 15 EUROPE: LEVEL OF RISK, TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 16 CHINA: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 17 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 18 RESPIRATORY DIAGNOSTICS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2022−2024
  • TABLE 19 IMPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 20 EXPORT DATA FOR HS CODE 901819, BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 21 AVERAGE SELLING PRICE TREND OF RESPIRATORY DIAGNOSTIC PRODUCTS, BY REGION, 2021–2023 (USD)
  • TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
  • TABLE 23 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
  • TABLE 24 RESPIRATORY DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2024−2025
  • TABLE 25 RESPIRATORY DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 26 CASE STUDY 1: ACUPEBBLE SA100 – TRANSFORMING SLEEP APNEA DIAGNOSIS
  • TABLE 27 CASE STUDY 2: REMOTE MONITORING SOLUTION FOR COVID-19 PATIENTS IN INDONESIA
  • TABLE 28 CASE STUDY 3: EFFECTIVE MANAGEMENT OF A 71-YEAR-OLD COPD PATIENT WITH ACUTE EXACERBATIONS
  • TABLE 29 RESPIRATORY DIAGNOSTICS MARKET: REIMBURSEMENT SCENARIO
  • TABLE 30 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 31 RESPIRATORY DIAGNOSTICS MARKET FOR INSTRUMENTS & DEVICES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 32 RESPIRATORY DIAGNOSTICS MARKET FOR ASSAYS & REAGENTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 33 RESPIRATORY DIAGNOSTICS MARKET FOR SERVICES & SOFTWARE, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 34 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 35 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 36 RESPIRATORY DIAGNOSTICS MARKET FOR MECHANICAL TESTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 37 RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 38 RESPIRATORY DIAGNOSTICS MARKET FOR PULMONARY FUNCTION TESTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 39 SPIROMETRY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 40 SPIROMETRY TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS)
  • TABLE 41 PEAK FLOW TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 42 PEAK FLOW TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS)
  • TABLE 43 OTHER PULMONARY TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 44 OTHER PULMONARY TESTS MARKET, BY REGION, 2022–2030 (THOUSAND UNITS)
  • TABLE 45 OBSTRUCTIVE SLEEP APNEA DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 46 OTHER MECHANICAL TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 47 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 48 RESPIRATORY DIAGNOSTICS MARKET FOR IMAGING TESTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 49 X-RAY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 50 COMPUTED TOMOGRAPHY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 51 MAGNETIC RESONANCE IMAGING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 52 POSITRON EMISSION TOMOGRAPHY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 53 OTHER IMAGING TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 54 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 55 RESPIRATORY DIAGNOSTICS MARKET FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 56 IMMUNODIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 57 BIOCHEMICAL TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 58 MICROSCOPY MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 59 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 60 RESPIRATORY DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 61 PCR MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 62 NUCLEIC ACID AMPLIFICATION TEST MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 63 IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 64 DNA SEQUENCING & NEXT-GENERATION SEQUENCING MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 65 MICROARRAYS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 66 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 67 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 68 RESPIRATORY DIAGNOSTICS MARKET FOR TUBERCULOSIS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 69 RESPIRATORY DIAGNOSTICS MARKET FOR ASTHMA, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 70 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 71 RESPIRATORY DIAGNOSTICS MARKET FOR LUNG CANCER, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 72 NON-SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 73 SMALL-CELL LUNG CANCER MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 74 OTHER LUNG CANCERS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 75 RESPIRATORY DIAGNOSTICS MARKET FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 76 RESPIRATORY DIAGNOSTICS MARKET FOR PNEUMONIA, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 77 RESPIRATORY DIAGNOSTICS MARKET FOR OTHER DISEASES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 78 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 79 SYNDROMIC DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 80 ETIOLOGICAL DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 81 PROGNOSIS DIAGNOSIS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 82 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 83 RESPIRATORY DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 84 RESPIRATORY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 85 RESPIRATORY DIAGNOSTICS MARKET FOR LONG-TERM CARE & SPECIALTY CENTERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 86 RESPIRATORY DIAGNOSTICS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 87 RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 88 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 89 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 91 NORTH AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 92 NORTH AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 93 NORTH AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 94 NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 95 NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 97 NORTH AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 98 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 99 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 100 US: KEY MACROINDICATORS
  • TABLE 101 US: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 102 US: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 103 US: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 104 US: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 105 US: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 106 US: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 107 US: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 108 US: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 109 US: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 110 US: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 111 US: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 112 CANADA: KEY MACROINDICATORS
  • TABLE 113 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 114 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 115 CANADA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 116 CANADA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 117 CANADA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 118 CANADA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 119 CANADA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 120 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 121 CANADA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 122 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 123 CANADA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 124 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 125 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 126 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 127 EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 128 EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 129 EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 130 EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 131 EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 132 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 133 EUROPE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 134 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 135 EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 136 GERMANY: KEY MACROINDICATORS
  • TABLE 137 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 138 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 139 GERMANY: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 140 GERMANY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 141 GERMANY: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 142 GERMANY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 143 GERMANY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 144 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 145 GERMANY: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 146 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 147 GERMANY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 148 UK: KEY MACROINDICATORS
  • TABLE 149 UK: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 150 UK: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 151 UK: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 152 UK: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 153 UK: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 154 UK: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 155 UK: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 156 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 157 UK: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 158 UK: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 159 UK: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 160 FRANCE: KEY MACROINDICATORS
  • TABLE 161 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 162 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 163 FRANCE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 164 FRANCE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 165 FRANCE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 166 FRANCE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 167 FRANCE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 168 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 169 FRANCE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 170 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 171 FRANCE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 172 ITALY: KEY MACROINDICATORS
  • TABLE 173 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 174 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 175 ITALY: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 176 ITALY: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 177 ITALY: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 178 ITALY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 179 ITALY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 180 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 181 ITALY: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 182 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 183 ITALY: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 184 SPAIN: KEY MACROINDICATORS
  • TABLE 185 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 186 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 187 SPAIN: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 188 SPAIN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 189 SPAIN: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 190 SPAIN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 191 SPAIN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 192 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 193 SPAIN: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 194 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 195 SPAIN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 196 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 197 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 198 REST OF EUROPE: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 199 REST OF EUROPE: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 200 REST OF EUROPE: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 201 REST OF EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 202 REST OF EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 203 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 204 REST OF EUROPE: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 205 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 206 REST OF EUROPE: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 208 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 209 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 210 ASIA PACIFIC: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 211 ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 212 ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 214 ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 215 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 216 ASIA PACIFIC: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 217 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 218 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 219 JAPAN: KEY MACROINDICATORS
  • TABLE 220 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 221 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 222 JAPAN: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 223 JAPAN: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 224 JAPAN: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 225 JAPAN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 226 JAPAN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 227 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 228 JAPAN: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 229 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 230 JAPAN: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 231 CHINA: KEY MACROINDICATORS
  • TABLE 232 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 233 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 234 CHINA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 235 CHINA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 236 CHINA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 237 CHINA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 238 CHINA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 239 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 240 CHINA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 241 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 242 CHINA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 243 INDIA: KEY MACROINDICATORS
  • TABLE 244 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 245 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 246 INDIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 247 INDIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 248 INDIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 249 INDIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 250 INDIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 251 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 252 INDIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 253 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 254 INDIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 255 AUSTRALIA: KEY MACROINDICATORS
  • TABLE 256 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 257 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 258 AUSTRALIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 259 AUSTRALIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 260 AUSTRALIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 261 AUSTRALIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 262 AUSTRALIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 263 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 264 AUSTRALIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 265 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 266 AUSTRALIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 267 SOUTH KOREA: KEY MACROINDICATORS
  • TABLE 268 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 269 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 270 SOUTH KOREA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 271 SOUTH KOREA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 272 SOUTH KOREA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 273 SOUTH KOREA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 274 SOUTH KOREA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 275 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 276 SOUTH KOREA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 277 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 278 SOUTH KOREA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 279 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 280 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 281 REST OF ASIA PACIFIC: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 282 REST OF ASIA PACIFIC: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 283 REST OF ASIA PACIFIC: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 284 REST OF ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 285 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 286 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 287 REST OF ASIA PACIFIC: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 288 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 289 REST OF ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 290 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 291 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 292 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 293 LATIN AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 294 LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 295 LATIN AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 296 LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 297 LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 298 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 299 LATIN AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 300 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 301 LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 302 BRAZIL: KEY MACROINDICATORS
  • TABLE 303 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 304 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 305 BRAZIL: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 306 BRAZIL: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 307 BRAZIL: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 308 BRAZIL: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 309 BRAZIL: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 310 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 311 BRAZIL: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 312 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 313 BRAZIL: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 314 MEXICO: KEY MACROINDICATORS
  • TABLE 315 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 316 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 317 MEXICO: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 318 MEXICO: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 319 MEXICO: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 320 MEXICO: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 321 MEXICO: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 322 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 323 MEXICO: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 324 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 325 MEXICO: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 326 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 327 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 328 REST OF LATIN AMERICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 329 REST OF LATIN AMERICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 330 REST OF LATIN AMERICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 331 REST OF LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 332 REST OF LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 333 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 334 REST OF LATIN AMERICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 335 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 336 REST OF LATIN AMERICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 337 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY REGION, 2022–2030 (USD MILLION)
  • TABLE 338 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 339 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 340 MIDDLE EAST & AFRICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 341 MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 342 MIDDLE EAST & AFRICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 343 MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 344 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 345 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 346 MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 347 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 348 MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 349 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 350 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 351 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 352 GCC COUNTRIES: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 353 GCC COUNTRIES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 354 GCC COUNTRIES: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 355 GCC COUNTRIES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 356 GCC COUNTRIES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 357 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 358 GCC COUNTRIES: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 359 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 360 GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 361 KINGDOM OF SAUDI ARABIA: KEY MACROINDICATORS
  • TABLE 362 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 363 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 364 KINGDOM OF SAUDI ARABIA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 365 KINGDOM OF SAUDI ARABIA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 366 KINGDOM OF SAUDI ARABIA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 367 KINGDOM OF SAUDI ARABIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 368 KINGDOM OF SAUDI ARABIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 369 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 370 KINGDOM OF SAUDI ARABIA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 371 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 372 KINGDOM OF SAUDI ARABIA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 373 UNITED ARAB EMIRATES: KEY MACROINDICATORS
  • TABLE 374 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 375 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 376 UNITED ARAB EMIRATES: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 377 UNITED ARAB EMIRATES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 378 UNITED ARAB EMIRATES: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 379 UNITED ARAB EMIRATES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 380 UNITED ARAB EMIRATES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 381 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 382 UNITED ARAB EMIRATES: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 383 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 384 UNITED ARAB EMIRATES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 385 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 386 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 387 OTHER GCC COUNTRIES: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 388 OTHER GCC COUNTRIES: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 389 OTHER GCC COUNTRIES: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 390 OTHER GCC COUNTRIES: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 391 OTHER GCC COUNTRIES: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 392 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 393 OTHER GCC COUNTRIES: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 394 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 395 OTHER GCC COUNTRIES: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 396 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2030 (USD MILLION)
  • TABLE 397 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2022–2030 (USD MILLION)
  • TABLE 398 REST OF MIDDLE EAST & AFRICA: MECHANICAL TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 399 REST OF MIDDLE EAST & AFRICA: PULMONARY FUNCTION TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 400 REST OF MIDDLE EAST & AFRICA: IMAGING TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 401 REST OF MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 402 REST OF MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 403 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 404 REST OF MIDDLE EAST & AFRICA: LUNG CANCER MARKET, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 405 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2022–2030 (USD MILLION)
  • TABLE 406 REST OF MIDDLE EAST & AFRICA: RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 407 RESPIRATORY DIAGNOSTIC MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, JANUARY 2021–DECEMBER 2024
  • TABLE 408 RESPIRATORY DIAGNOSTICS MARKET: DEGREE OF COMPETITION, 2023
  • TABLE 409 RESPIRATORY DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
  • TABLE 410 RESPIRATORY DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 411 RESPIRATORY DIAGNOSTICS MARKET: TEST TYPE FOOTPRINT
  • TABLE 412 RESPIRATORY DIAGNOSTICS MARKET: DISEASE TYPE FOOTPRINT
  • TABLE 413 RESPIRATORY DIAGNOSTICS MARKET: END-USER FOOTPRINT
  • TABLE 414 RESPIRATORY DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 415 RESPIRATORY DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 416 RESPIRATORY DIAGNOSTICS MARKET: PRODUCT & SERVICE LAUNCHES AND APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 417 RESPIRATORY DIAGNOSTICS MARKET: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 418 RESPIRATORY DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 419 RESPIRATORY DIAGNOSTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024
  • TABLE 420 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW
  • TABLE 421 KONINKLIJKE PHILIPS N.V.: PRODUCTS & SERVICES OFFERED
  • TABLE 422 KONINKLIJKE PHILIPS N.V.: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 423 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 424 KONINKLIJKE PHILIPS N.V.: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 425 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 426 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED
  • TABLE 427 BECTON, DICKINSON AND COMPANY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 428 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 429 ABBOTT LABORATORIES: COMPANY OVERVIEW
  • TABLE 430 ABBOTT LABORATORIES: PRODUCTS & SERVICES OFFERED
  • TABLE 431 ABBOTT LABORATORIES: PRODUCT APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 432 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 433 THERMO FISHER SCIENTIFIC INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 434 THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 435 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 436 GE HEALTHCARE TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 437 GE HEALTHCARE TECHNOLOGIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 438 GE HEALTHCARE TECHNOLOGIES, INC.: PRODUCT & SERVICE LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 439 GE HEALTHCARE TECHNOLOGIES, INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 440 GE HEALTHCARE TECHNOLOGIES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024
  • TABLE 441 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 442 BIO-RAD LABORATORIES, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 443 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 444 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 445 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 446 BIOMÉRIEUX: PRODUCTS & SERVICES OFFERED
  • TABLE 447 BIOMÉRIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 448 BIOMÉRIEUX: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 449 REVVITY, INC.: COMPANY OVERVIEW
  • TABLE 450 REVVITY, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 451 REVVITY, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 452 REVVITY, INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 453 SEEGENE INC.: COMPANY OVERVIEW
  • TABLE 454 SEEGENE INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 455 SEEGENE INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 456 SEEGENE INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 457 SEEGENE INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 458 SEEGENE INC.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024
  • TABLE 459 NIHON KOHDEN CORPORATION: COMPANY OVERVIEW
  • TABLE 460 NIHON KOHDEN CORPORATION: PRODUCTS & SERVICES OFFERED
  • TABLE 461 VITALOGRAPH: COMPANY OVERVIEW
  • TABLE 462 VITALOGRAPH: PRODUCTS & SERVICES OFFERED
  • TABLE 463 VITALOGRAPH: PRODUCT & SERVICE LAUNCHES & APPROVALS, JANUARY 2021–DECEMBER 2024
  • TABLE 464 VITALOGRAPH: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 465 SDI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 466 SDI DIAGNOSTICS: PRODUCTS & SERVICES OFFERED
  • TABLE 467 RESMED INC.: COMPANY OVERVIEW
  • TABLE 468 RESMED INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 469 RESMED INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 470 RESMED INC.: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 471 RESMED INC.: OTHER DEVELOPMENTS, JANUARY 2021–DECEMBER 2024
  • TABLE 472 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 473 SIEMENS HEALTHINEERS AG: PRODUCTS & SERVICES OFFERED
  • TABLE 474 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 475 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 476 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021–DECEMBER 2024
  • TABLE 477 COSMED SRL: COMPANY OVERVIEW
  • TABLE 478 COSMED SRL: PRODUCTS & SERVICES OFFERED
  • TABLE 479 COSMED SRL: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 480 COSMED SRL: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 481 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 482 HOLOGIC, INC.: PRODUCTS & SERVICES OFFERED
  • TABLE 483 HOLOGIC, INC.: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 484 HOLOGIC, INC.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 485 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 486 QIAGEN N.V.: PRODUCTS & SERVICES OFFERED
  • TABLE 487 QIAGEN N.V.: PRODUCT LAUNCHES, JANUARY 2021–DECEMBER 2024
  • TABLE 488 QIAGEN N.V.: DEALS, JANUARY 2021–DECEMBER 2024
  • TABLE 489 QIAGEN N.V.: OTHER DEVELOPMENTS, JANUARY 2021–MARCH 2024
LIST OF FIGURES
 
  • FIGURE 1 RESPIRATORY DIAGNOSTICS MARKET: MARKET & REGIONAL SPREAD
  • FIGURE 2 RESPIRATORY DIAGNOSTICS MARKET: YEARS CONSIDERED
  • FIGURE 3 RESEARCH DESIGN
  • FIGURE 4 RESPIRATORY DIAGNOSTICS MARKET: KEY PRIMARY SOURCES
  • FIGURE 5 RESPIRATORY DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
  • FIGURE 6 RESPIRATORY DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 9 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION
  • FIGURE 10 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
  • FIGURE 11 REVENUE SHARE ANALYSIS ILLUSTRATION: KONINKLIJKE PHILIPS N.V. (2023)
  • FIGURE 12 SUPPLY-SIDE ANALYSIS: RESPIRATORY DIAGNOSTICS MARKET (2023)
  • FIGURE 13 RESPIRATORY DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 14 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 15 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 16 RESPIRATORY DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 17 RESPIRATORY DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 18 RESPIRATORY DIAGNOSTICS MARKET, BY TEST TYPE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 19 RESPIRATORY DIAGNOSTICS MARKET, BY DISEASE TYPE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 20 RESPIRATORY DIAGNOSTICS MARKET, BY DIAGNOSIS TYPE, 2024 VS. 2030 (USD MILLION)
  • FIGURE 21 RESPIRATORY DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2030 (USD MILLION)
  • FIGURE 22 GEOGRAPHIC SNAPSHOT OF RESPIRATORY DIAGNOSTICS MARKET
  • FIGURE 23 RISING PREVALENCE OF RESPIRATORY DISEASES TO PROPEL MARKET
  • FIGURE 24 INSTRUMENTS & DEVICES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA (2023)
  • FIGURE 25 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 26 INDIA TO GROW AT HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 27 RESPIRATORY DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 28 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) DALY FOR INDIVIDUALS IN AUSTRALIA, BY AGE (2023)
  • FIGURE 29 GLOBAL GERIATRIC POPULATION, BY REGION
  • FIGURE 30 RESPIRATORY DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 31 NUMBER OF PATENTS PUBLISHED, JANUARY 2014–DECEMBER 2024
  • FIGURE 32 TOP PATENT APPLICANTS AND OWNERS (COMPANIES/INSTITUTES) FOR RESPIRATORY DIAGNOSTICS DEVICES (JANUARY 2014– DECEMBER 2024)
  • FIGURE 33 TOP PATENT APPLICANTS, BY JURISDICTION, JANUARY 2014−DECEMBER 2024
  • FIGURE 34 AVERAGE SELLING PRICE OF SPIROMETERS, BY KEY PLAYER (2024)
  • FIGURE 35 AVERAGE SELLING PRICE OF PEAK FLOWMETERS, BY KEY PLAYER (2024)
  • FIGURE 36 RESPIRATORY DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 37 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR RESPIRATORY DIAGNOSTIC DEVICES
  • FIGURE 38 KEY BUYING CRITERIA FOR RESPIRATORY DIAGNOSTIC DEVICES
  • FIGURE 39 RESPIRATORY DIAGNOSTICS MARKET: ADJACENT MARKETS
  • FIGURE 40 RESPIRATORY DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 41 RESPIRATORY DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 42 RESPIRATORY DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 43 RESPIRATORY DIAGNOSTICS MARKET: NUMBER OF DEALS, 2020–2024
  • FIGURE 44 RESPIRATORY DIAGNOSTICS MARKET: IMPACT OF AI/GEN AI
  • FIGURE 45 RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 46 NORTH AMERICA: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 47 ASIA PACIFIC: RESPIRATORY DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 48 RESPIRATORY DIAGNOSTICS MARKET: REVENUE ANALYSIS OF KEY PLAYERS, 2019−2023
  • FIGURE 49 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET (2023)
  • FIGURE 50 RANKING OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET, 2023
  • FIGURE 51 RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 52 RESPIRATORY DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 53 RESPIRATORY DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 54 RESPIRATORY DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 55 R&D EXPENDITURE OF KEY PLAYERS IN RESPIRATORY DIAGNOSTICS MARKET, 2022−2024
  • FIGURE 56 EV/EBITDA OF KEY VENDORS
  • FIGURE 57 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 58 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023)
  • FIGURE 59 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024)
  • FIGURE 60 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2023)
  • FIGURE 61 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 62 GE HEALTHCARE TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 63 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 64 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 65 REVVITY, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 66 SEEGENE INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 67 NIHON KOHDEN CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 68 RESMED INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 69 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 70 HOLOGIC, INC.: COMPANY SNAPSHOT (2024)
  • FIGURE 71 QIAGEN N.V.: COMPANY SNAPSHOT (2023)

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources; directories; databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the respiratory diagnostics market. It was also used to obtain important information about the key players, market classification and segmentation according to industry trends to the bottommost level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, chief medical information officers related to the respiratory diagnostics markets. Primary sources from the demand side include professionals from hospitals and clinics, diagnostics laboratories, professors, and researcher.

A breakdown of the primary respondents is provided below:

Respiratory Diagnostics Market

Note 1: C-level primaries include CEOs, COOs, CTOs, and VPs.

Note 2: Other primaries include sales managers, marketing managers, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2023: Tier 1 = >USD 500 million, Tier 2 = USD 200 million to USD 500 million, and Tier 3 = < USD 200 million.

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the respiratory diagnostics market was arrived at after data triangulation from three different approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach

Respiratory Diagnostics Market

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The following figure shows the market validation, source structure, and data triangulation methodology implemented in the market engineering process.

Market Definition

Respiratory diagnostic devices assess and monitor the functioning of the respiratory system and play a crucial role in diagnosing and managing various respiratory conditions. They include a wide range of equipment that aids in breathing, improves pulmonary function, and assists in the removal of mucus from the airways. Some of the respiratory diagnostic tests include mechanical tests such as Spirometry, Pulse Oximetry, Bronchoscopy, Diagnostic Imaging tests, and in vitro diagnostic tests.

Stakeholders

  • Respiratory diagnostic device manufacturers and distributors
  • Healthcare institutions (hospitals, laboratories, medical schools, and outpatient clinics)
  • Research institutes
  • Contract manufacturing organizations (CMOs)
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors
  • Market research and consulting firms

Report Objectives

  • To define, describe, and forecast the respiratory diagnostics market by product and service, test type, disease indication, type of diagnosis, end user, and region
  • To provide detailed information about the key factors influencing the market growth, such as drivers, restraints, opportunities, challenges, and industry trends
  • To strategically analyze the regulatory scenario, Porter’s Five Forces, value chain, supply chain, ecosystem market/map, recession, and patents in the market
  • To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall respiratory diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
  • To strategically profile the key players in this market and comprehensively analyze their market shares and core competencies
  • To strategically analyze the respiratory diagnostics market in five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To track and analyze competitive developments such as acquisitions, product launches, partnerships, and expansions in the respiratory diagnostics market.

Previous Versions of this Report

Respiratory Diagnostics Market by Product & Services (Devices, Reagents, Software), Test (PFT, Peak Flow, Spirometry), OSA, Imaging (X-ray, CT, MRI, PET), Molecular (PCR, DNA Sequencing), Indication (Lung Cancer, Asthma, COPD, TB) - Global Forecast to 2029

Report Code MD 4740
Published in Nov, 2023, By MarketsandMarkets™

Respiratory Diagnostics Market by Product & Service (Instruments/Devices, Kits/Reagents), Test Type (Pulmonary Function Test, Imaging Test), Disease (TB, Lung Cancer, COPD), End User (Reference Laboratories, Physician Offices)

Report Code MD 4740
Published in Nov, 2016, By MarketsandMarkets™

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in Respiratory Diagnostics Market

+1-888600-6441

Corporate Office Hours

+1-888600-6441

US/Can Toll Free

+44-800-368-9399

UK Office Hours

©2024 Marketsandmarkets Research Private Ltd. All Rights Reserved.

DMCA.com Protection Status